New imaging technique could transform diagnosis and treatment of steatotic liver disease

Tokyo University of ScienceJan 9 2024

Steatotic liver disease (SLD), previously known as non-alcoholic fatty liver disease, which includes a range of conditions caused by fat build-up in the liver due to abnormal lipid metabolism, affects about 25% of the population worldwide, making it the most common liver disorder. Often referred to as "silent liver disease," SLD progresses without noticeable symptoms and can lead to more severe conditions like cirrhosis (liver scarring) and liver cancer.

A liver biopsy-;an invasive procedure involving liver tissue sample extraction from the body-;is the conventional method of testing for SLD. To simplify detection, a research team led by Professor Kohei Soga of Tokyo University of Science (TUS) had previously introduced near-infrared hyperspectral imaging (NIR-HSI) as a non-invasive method to visualize the total lipid content in the liver. NIR light, with longer wavelengths (800–2500 nm) than ultraviolet and visible light shows absorption attributed to various organic substances, including biomolecules in tissues, enabling the identification of fat distribution in the liver.

Now, in a new study published in the journal Scientific Reports on 23 November 2023, the research team, including Prof. Kohei Soga, Associate Professor Masakazu Umezawa, and Associate Professor Masao Kamimura from TUS, and Professor Naoko Ohtani from Osaka Metropolitan University, has improved upon this method by having a machine learning model differentiate the type of lipids present in the liver at a pixel-by-pixel level. The framework differentiates lipids based on the hydrocarbon chain length (HCL) and degree of saturation (DS) of fatty acids, helping estimate the risk of SLD progression, steatohepatitis (NASH), and SLD/NASH-associated liver cancer.

"In addition to qualitative information, such as the total lipid content, we can now also visualize qualitative information, such as the characteristics of the distribution of fatty acids contained in lipids, mainly triglycerides," says Dr. Umezawa.

Notably, identifying lipids based on molecular composition using NIR-HSI faced challenges due to the overlapping absorption spectra of various biomolecules. To address this, the researchers used a support vector regression machine learning model, which was trained to recognize the composition of 16 fatty acids. This training data was obtained through gas chromatography analysis of liver samples of mice that were fed diets of varying fat content. By applying machine learning to NIR-HSI data, it became possible to interpret the spectral information in terms of the distribution of fat (DS and HCL) within the liver.

DS, indicating the double bonds or degree of saturation of the fatty acids, is calculated as the CH₂ fraction from the sum of the CH and CH₂ numbers. HCL, representing the fatty acid chain length, is determined by the ratio of CH₃ + CH₂ + CH + 1(COOH) groups to the number of CH₃ groups. Using this method, the researchers successfully determined the fatty acid composition in mice livers, revealing correlations with the fat contents in their diets. For instance, the livers of mice on a diet rich in saturated fats like palmitic acid and myristic acid exhibited a notably high DS, whereas mice fed with unsaturated fats such as α-linoleic acid showed a low DS.

The DS, HCL, and total lipid content were depicted as a color map, offering a unique visual representation of fat distribution in the liver, thus simplifying the diagnosis of fatty liver conditions. "Visualization of lipid distribution in higher-dimensional information rather than simply using total lipid content as a single parameter provides a novel tool for revealing the pathophysiological conditions of liver diseases and metabolism," remarks Dr. Umezawa.

Indeed, by providing a rapid and label-free technique to identify fatty liver, which affects a large population segment, the method could be a potential alternative to invasive liver biopsy procedures, transforming liver care.

This novel framework could also find potential applications in pharmacological research, such as drug metabolism, toxicity, and efficacy; studies on metabolic disorders through metabolic imaging; and identifying responders and non-responders in clinical trials. The researchers also expect the framework to find applications in identifying personalized nutritional strategies-;tailoring plans and optimizing interventions for better nutrition-;through biomarker identification and treatment response prediction. In summary, the novel framework developed by the researchers could revolutionize healthcare and related research.